HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS)

Clinical trials for HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.

Never miss a new study

Get alerted when new HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS) trials appear

Sign up with your email to follow new studies for HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for MDS patients: targeted drug trial enters final phase

Disease control Recruiting now

This study is testing two different drugs, ivosidenib and azacitidine, for adults with a type of blood cancer called myelodysplastic syndromes (MDS) who have a specific genetic change (IDH1 mutation) and have not yet received standard treatment. Participants will be randomly assi…

Matched conditions: HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS)

Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS)

Get alerted when new HYPOMETHYLATING AGENT (HMA) NAIVE MYELODYSPLASTIC SYNDROMES (MDS) trials appear

New hope for MDS patients: targeted drug trial enters final phase